Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)
Authors
Keywords
-
Journal
Modern Rheumatology
Volume -, Issue -, Pages 1-9
Publisher
Informa UK Limited
Online
2018-10-18
DOI
10.1080/14397595.2018.1538004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies
- (2017) James C.-C. Wei et al. International Journal of Rheumatic Diseases
- Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
- (2017) Gerard Bruin et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis
- (2016) Deepak R Jadon et al. ANNALS OF THE RHEUMATIC DISEASES
- Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis
- (2016) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- A multicenter, open-label, long-term study of three-year infliximab administration in Japanese patients with ankylosing spondylitis
- (2016) Shigeto Kobayashi et al. Modern Rheumatology
- Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability
- (2015) Jacob S. Lee et al. IMMUNITY
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- The IL-23–IL-17 axis in inflammatory arthritis
- (2015) Erik Lubberts Nature Reviews Rheumatology
- Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
- (2015) Dominique Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
- (2015) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study
- (2014) Carmen Stolwijk et al. ANNALS OF THE RHEUMATIC DISEASES
- The concept of spondyloarthritis: Where are we now?
- (2014) Neha Garg et al. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
- A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis
- (2014) Shigeto Kobayashi et al. Modern Rheumatology
- Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review
- (2014) Konstantinos Kotsis et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis
- (2013) Carmen Stolwijk et al. ANNALS OF THE RHEUMATIC DISEASES
- A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: Are Japanese phase I studies still needed?
- (2013) Koji Chiba et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Treatment Challenges in Axial Spondylarthritis and Future Directions
- (2013) Joachim Sieper Current Rheumatology Reports
- Ankylosing Spondylitis: Chinese Perspective, Clinical Phenotypes, and Associated Extra-articular Systemic Features
- (2013) Huei-Huang Ho et al. Current Rheumatology Reports
- Epidemiology of Spondyloarthritis
- (2012) Carmen Stolwijk et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents
- (2012) Xin Gao et al. JOURNAL OF MEDICAL ECONOMICS
- 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
- (2011) J. Braun et al. ANNALS OF THE RHEUMATIC DISEASES
- Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome
- (2011) X. Baraliakos et al. RHEUMATOLOGY
- Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
- (2008) D van der Heijde et al. ANNALS OF THE RHEUMATIC DISEASES
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started